272 related articles for article (PubMed ID: 9397180)
1. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease.
Shetty BV; Kosa MB; Khalil DA; Webber S
Antimicrob Agents Chemother; 1996 Jan; 40(1):110-4. PubMed ID: 8787890
[TBL] [Abstract][Full Text] [Related]
3. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.
Zhang KE; Wu E; Patick AK; Kerr B; Zorbas M; Lankford A; Kobayashi T; Maeda Y; Shetty B; Webber S
Antimicrob Agents Chemother; 2001 Apr; 45(4):1086-93. PubMed ID: 11257019
[TBL] [Abstract][Full Text] [Related]
4. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
[TBL] [Abstract][Full Text] [Related]
5. Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.
Gaucher B; Rouquayrol M; Roche D; Greiner J; Aubertin AM; Vierling P
Org Biomol Chem; 2004 Feb; 2(3):345-57. PubMed ID: 14747863
[TBL] [Abstract][Full Text] [Related]
6. Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.
Melnick M; Reich SH; Lewis KK; Mitchell LJ; Nguyen D; Trippe AJ; Dawson H; Davies JF; Appelt K; Wu BW; Musick L; Gehlhaar DK; Webber S; Shetty B; Kosa M; Kahil D; Andrada D
J Med Chem; 1996 Jul; 39(14):2795-811. PubMed ID: 8709110
[TBL] [Abstract][Full Text] [Related]
7. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
[TBL] [Abstract][Full Text] [Related]
8. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
[TBL] [Abstract][Full Text] [Related]
9. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.
Bold G; Fässler A; Capraro HG; Cozens R; Klimkait T; Lazdins J; Mestan J; Poncioni B; Rösel J; Stover D; Tintelnot-Blomley M; Acemoglu F; Beck W; Boss E; Eschbach M; Hürlimann T; Masso E; Roussel S; Ucci-Stoll K; Wyss D; Lang M
J Med Chem; 1998 Aug; 41(18):3387-401. PubMed ID: 9719591
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.
Randolph JT; Huang PP; Flosi WJ; DeGoey D; Klein LL; Yeung CM; Flentge C; Sun M; Zhao C; Dekhtyar T; Mo H; Colletti L; Kati W; Marsh KC; Molla A; Kempf DJ
Bioorg Med Chem; 2006 Jun; 14(12):4035-46. PubMed ID: 16504523
[TBL] [Abstract][Full Text] [Related]
11. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
[TBL] [Abstract][Full Text] [Related]
12. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
Skulnick HI; Johnson PD; Aristoff PA; Morris JK; Lovasz KD; Howe WJ; Watenpaugh KD; Janakiraman MN; Anderson DJ; Reischer RJ; Schwartz TM; Banitt LS; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Dolak LA; Seest EP; Schwende FJ; Rush BD; Howard GM; Toth LN; Wilkinson KR; Romines KR
J Med Chem; 1997 Mar; 40(7):1149-64. PubMed ID: 9089336
[TBL] [Abstract][Full Text] [Related]
14. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.
Fässler A; Bold G; Capraro HG; Cozens R; Mestan J; Poncioni B; Rösel J; Tintelnot-Blomley M; Lang M
J Med Chem; 1996 Aug; 39(16):3203-16. PubMed ID: 8759643
[TBL] [Abstract][Full Text] [Related]
15. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
[TBL] [Abstract][Full Text] [Related]
16. New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors.
Kim CU; McGee LR; Krawczyk SH; Harwood E; Harada Y; Swaminathan S; Bischofberger N; Chen MS; Cherrington JM; Xiong SF; Griffin L; Cundy KC; Lee A; Yu B; Gulnik S; Erickson JW
J Med Chem; 1996 Aug; 39(18):3431-4. PubMed ID: 8784440
[No Abstract] [Full Text] [Related]
17. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
Miller JF; Brieger M; Furfine ES; Hazen RJ; Kaldor I; Reynolds D; Sherrill RG; Spaltenstein A
Bioorg Med Chem Lett; 2005 Aug; 15(15):3496-500. PubMed ID: 15990305
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.
Reich SH; Melnick M; Pino MJ; Fuhry MA; Trippe AJ; Appelt K; Davies JF; Wu BW; Musick L
J Med Chem; 1996 Jul; 39(14):2781-94. PubMed ID: 8709109
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
Mimoto T; Kato R; Takaku H; Nojima S; Terashima K; Misawa S; Fukazawa T; Ueno T; Sato H; Shintani M; Kiso Y; Hayashi H
J Med Chem; 1999 May; 42(10):1789-802. PubMed ID: 10346931
[TBL] [Abstract][Full Text] [Related]
20. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
Perez MA; Fernandes PA; Ramos MJ
J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
